Skip to content Skip to footer
Dr

Joshua Wong

Email: 

Overview

Background

I am a Postdoctoral Research Fellow at The University of Queensland’s Frazer Institute, working in Professor Fernando Guimaraes’ laboratory. My research focuses on developing novel cancer immunotherapies, including cellular therapies and small biologics such as antibodies, to address unmet clinical needs in aggressive cancers. My work spans triple-negative breast cancer (TNBC) and aggressive lymphomas, with an emphasis on developing targeted, next-generation therapeutic approaches to improve treatment outcomes for patients.

Availability

Dr Joshua Wong is:
Available for supervision

Qualifications

  • Bachelor (Honours) of Immunology, The University of Queensland
  • Doctor of Philosophy of Animal Immunology, The University of Queensland

Works

Search Professor Joshua Wong’s works on UQ eSpace

9 works between 2023 and 2026

1 - 9 of 9 works

2026

Other Outputs

ROR1 binding proteins and uses thereof

Souza-Fonseca-Guimaraes, Fernando and Wong, Joshua K. M. (2026). ROR1 binding proteins and uses thereof. PAT-02553.

ROR1 binding proteins and uses thereof

2026

Journal Article

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

Wong, Joshua K. M., Lam, Pui Yeng, Coleborn, Elaina, Alim, Louisa, Jose, Jiya, Tu, Cui, Antczak, Magdalena, Dietmair, Bettina, Hagh, Arghavan Golbaz, Noronha, Lucia, Cheetham, Seth W., Hooper, John, Beavis, Paul A., Merino, Delphine, Berthelet, Jean, Aoude, Lauren G., McCart-Reed, Amy E., Lakhani, Sunil, Simpson, Peter T., Rossi, Gustavo R., Brooks, Andrew J., Jones, Martina L., Simpson, Fiona and Souza-Fonseca-Guimaraes, Fernando (2026). Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. Molecular Therapy, 34 (3), 1382-1398. doi: 10.1016/j.ymthe.2025.11.021

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy

2025

Journal Article

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

Lam, Pui Yeng, Omer, Natacha, Wong, Josh K. M., Tu, Cui, Alim, Louisa, Rossi, Gustavo R., Victorova, Maria, Tompkins, Hannah, Lin, Cheng-Yu, Mehdi, Ahmed M., Choo, Amos, Elliott, Melissa R., Coleborn, Elaina, Sun, Jane, Mercer, Timothy, Vittorio, Orazio, Dobson, Lachlan J., Mclellan, Alexander D., Brooks, Andrew, Tuong, Zewen Kelvin, Cheetham, Seth W., Nicholls, Wayne and Souza-Fonseca-Guimaraes, Fernando (2025). Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR. Clinical and Translational Medicine, 15 (1) e70140, 1-21. doi: 10.1002/ctm2.70140

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR

2024

Journal Article

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation

McCulloch, Timothy R., Rossi, Gustavo R., Alim, Louisa, Lam, Pui Yeng, Wong, Joshua K. M., Coleborn, Elaina, Kumari, Snehlata, Keane, Colm, Kueh, Andrew J., Herold, Marco J., Wilhelm, Christoph, Knolle, Percy A., Kane, Lawrence, Wells, Timothy J. and Souza-Fonseca-Guimaraes, Fernando (2024). Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation. Nature Communications, 15 (1) 9871, 1-16. doi: 10.1038/s41467-024-54232-y

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation

2024

Journal Article

A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy

Rossi, Gustavo R., Sun, Jane, Lin, Cheng‐Yu, Wong, Joshua K.M., Alim, Louisa, Lam, Pui Yeng, Khosrotehrani, Kiarash, Wolvetang, Ernst, Cheetham, Seth W., Derrick, Emily B., Amoako, Akwasi, Lehner, Christoph, Brooks, Andrew J., Beavis, Paul A. and Souza‐Fonseca‐Guimaraes, Fernando (2024). A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy. Immunology & Cell Biology, 102 (10), 1-11. doi: 10.1111/imcb.12820

A scalable, spin‐free approach to generate enhanced induced pluripotent stem cell–derived natural killer cells for cancer immunotherapy

2024

Journal Article

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer

Wong, Joshua K. M., McCulloch, Timothy R., Alim, Louisa, Omer, Natacha, Mehdi, Ahmed M., Tuong, Zewen Kelvin, Bonfim-Melo, Alexis, Chung, Eric, Nicol, Alice, Simpson, Fiona, Rhee, Handoo, Rossi, Gustavo Rodrigues and Souza-Fonseca-Guimaraes, Fernando (2024). TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. EBioMedicine, 104 105176, 1-15. doi: 10.1016/j.ebiom.2024.105176

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer

2024

Conference Publication

TGF-β signaling limits effector function capacity of NK cell anti-cancer immunity in human bladder cancer

Wong, Joshua, Rossi, Gustavo Rodrigues and Guimaraes, Fernando (2024). TGF-β signaling limits effector function capacity of NK cell anti-cancer immunity in human bladder cancer. Annual Meeting of the American Association of Immunologists (IMMUNOLOGY), Chicago, IL, United States, 3-7 May 2024. Cary, NC, United States: Oxford University Press. doi: 10.4049/jimmunol.212.supp.1431.4524

TGF-β signaling limits effector function capacity of NK cell anti-cancer immunity in human bladder cancer

2023

Conference Publication

Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2

McCulloch, Timothy R., Rossi, Gustavo Rodrigues, Lam, Allie, Wong, Joshua, Kane, Lawrence P., Herold, Marco, Wells, Timothy and Souza-Fonseca-Guimaraes, Fernando (2023). Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2. Immunology 2023™ Meeting, Washington, DC United States, 11-15 May 2023. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.72.28

Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2

2023

Journal Article

Weaponizing natural killer cells for solid cancer immunotherapy

Wong, Joshua K.M., Dolcetti, Riccardo, Rhee, Handoo, Simpson, Fiona and Souza-Fonseca-Guimaraes, Fernando (2023). Weaponizing natural killer cells for solid cancer immunotherapy. Trends in Cancer, 9 (2), 111-121. doi: 10.1016/j.trecan.2022.10.009

Weaponizing natural killer cells for solid cancer immunotherapy

Funding

Current funding

  • 2026 - 2027
    Developing Next-Generation Natural Killer Cell Immunotherapies Targeting Oncofetal Receptors in Solid Cancers
    Australia's Economic Accelerator Ignite Grants
    Open grant

Supervision

Availability

Dr Joshua Wong is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Dr Joshua Wong's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au